In the Netherlands, Royal DSM opened a new state-of-the-art biotechnology facility in Delft to accelerate DSM’s biotechnology research and development capabilities for applications in food and nutrition, feed, fuel, pharma and bio-based materials. Offering the broadest range of biotechnology specializations under one DSM roof, the center houses over 400 research and developments experts and builds on a solid history of nearly 150 years of fermentation and biotechnology innovation in Delft, the Netherlands.
Innovations currently under development include the production of fermentative steviol glycosides – the reduced-calorie, sweet-tasting molecules in the Stevia plant – as an answer to the growing global demand for sugar-reduced food and beverages; and, a new technology that turns an inedible agricultural by-product of rapeseed, or canola, into valuable plant protein for food.
The completion of this new biotechnology center is part of a €100 million investment program by DSM to scale up R&D in the Netherlands since 2013.